Published in Oncogene on May 28, 2007
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity (2009) 1.72
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Immunotherapy for ovarian cancer: what's next? J Clin Oncol (2010) 1.17
Treating rheumatic patients with a malignancy. Arthritis Res Ther (2011) 1.03
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun (2008) 1.01
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99
A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs. Vet Immunol Immunopathol (2009) 0.99
HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches. Apoptosis (2008) 0.99
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res (2010) 0.94
Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep (2012) 0.92
Sam68 modulates the promoter specificity of NF-κB and mediates expression of CD25 in activated T cells. Nat Commun (2013) 0.90
Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling. J Biol Chem (2013) 0.87
Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol (2009) 0.85
Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol (2009) 0.79
Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors. Biomed Res Int (2014) 0.78
Trends in cancer immunotherapy. Clin Med Insights Oncol (2010) 0.75